In relapsing MS, Mavenclad users' thinking scores rose
By MS Buddy ·
Summarized from European neurology, Nov 2026 · PubMed. AI-generated summary. Not medical advice.
Observational study · 173 people with MS who received Mavenclad
Research by Serkan Ozakbas, Ela Simay Zengin and 3 colleagues.
How did thinking and walking change for people with MS taking Mavenclad?
Key Takeaway
Among people with relapsing MS taking Mavenclad, thinking test scores improved, while a timed walking test took longer.

What They Found
Researchers followed 173 people with MS after they started cladribine (Mavenclad). Over two years, about 95% had no relapses. Brain scans showed no new signs of disease activity in about 97%. In a smaller group, scores improved on every thinking test used. Timed walking took longer over time, while results on a hand movement test did not change clearly.
Who Should Care and Why
This study followed people with MS who received Mavenclad, a drug used for relapsing MS. It looked at relapses and brain scans over two years. A smaller group also took thinking and movement tests. The thinking results may interest people concerned about changes in memory or focus. The walking results show that not every measure improved during follow-up.
Important Considerations
If you take Mavenclad, these results come from a review of records for 173 people, not a trial comparing treatments. The abstract does not say how many people took the thinking and movement tests. Without a comparison group, the study cannot show that Mavenclad caused the changes.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in European neurology by et al.. Reproduced from the PubMed record.
Cladribine tablets are an established oral immune reconstitution therapy for relapsing multiple sclerosis, with proven clinical and radiological efficacy. However, evidence regarding their effects on cognitive and physical outcomes in real-world settings remains limited. To assess the clinical, radiological, cognitive, and physical outcomes of cladribine treatment in people with Multiple Sclerosis (pwMS) over a follow-up of up to two years in a real-world cohort. A total of 173 patients with multiple sclerosis (pwMS) received cladribine treatment and were subsequently followed over time. Clinical data, including relapse rate, EDSS, and MRI findings, were collected annually. Cognitive (BICAMS: Brief International Cognitive Assessment for MS) and physical performance (T25FW: Timed-25-Foot Walking Test, N-HPT: Nine-Hole Peg Test) data of a subgroup of participants were collected at baseline, year 1, and year 2. The mean age was 36.75 ± 11.44, and the mean disease duration was 8.33 ± 6.85 years. Over a two-year follow-up, 94.8% of patients remained relapse-free, and MRI activity was absent in 96.5%. Significant improvements were observed in all BICAMS subtests (p < 0.05). While T25FW increased over years (p: 0.017), NHPT showed a similar trajectory (p>0.05). Cladribine demonstrated high efficacy in suppressing clinical and radiological activity while supporting cognitive stability.
Trials you could look into
This study looked at a treatment with MS trials currently recruiting or under way.
Listing a trial is not a recommendation. Eligibility is decided by the study team, and your neurologist is the person to ask first.
Categories
Explore more research
Related MS research

11/17/2026
A review suggests MS fatigue may reflect extra effort to control movement and incomplete recovery af
Read More
11/16/2026
Computer studies found MS fatigue surveys can give similar group results but different individual sc
Read More
11/17/2026
A review found exercise, therapy focused on thoughts and behavior, and self-management programs show
Read More
11/17/2026
Donated MS brain tissue showed damage in a vision hub. Mouse findings linked local immune cell activ
Read More
1/1/2026
A study of 318 people with MS linked lower thinking test scores to more sexual difficulties, with th
Read More
11/14/2026
In a study of people with MS, those with greater disability reported more voice problems and vocal f
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
